Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00193323 · ClinicalTrials.gov registry record · Phase 2
Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Non-Small Cell Lung Cancer in Elderly Patients
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 346
- Enrollment target
NCT00193323: Completed Phase 2 study, sponsored by SCRI Development Innovations.
NCT00193323 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 346 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (160% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00193323, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 346 participants
- Enrollment target
Study Summary
In this randomized trial, we attempt to further define optimal palliative chemotherapy for elderly patients with advanced non-small cell lung cancer by comparing single agent treatment with weekly docetaxel versus combination therapy with weekly docetaxel plus gemcitabine.
Interventions
- DRUG Docetaxel
- DRUG Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 346 participants |
| Start Date | 2001-08 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
What the finished NCT00193323 record still lists
NCT00193323 is an interventional study that assigns participants to a tested intervention. The registered 346 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (160% higher).
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT00193323 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00193323 about?
NCT00193323 is a clinical study titled "Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Non-Small Cell Lung Cancer in Elderly Patients". In this randomized trial, we attempt to further define optimal palliative chemotherapy for elderly patients with advanced non-small cell lung cancer by comparing single agent treatment with weekly docetaxel versus combination therapy with weekly docetaxel plus gemcitabine.
What is the current status of trial NCT00193323?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 346 participants. The study started on 2001-08. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00193323?
The interventions under investigation include: Docetaxel (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00193323?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00193323's enrollment target sits among peer trials
346 136th of 2000 higher than 1,865 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05267886 · 346 participants · Phase 4
CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock
- NCT06705842 · 346 participants · Phase 4
APPI-Cost Trial for Perforated Appendicitis
- NCT06932887 · 346 participants · Phase 3
The Beat Pain Better Trial
- NCT01742143 · 347 participants
Impact of ICCAN on Cancer Treatment Completion and Quality of Life
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia